THERAFLU FLU & SORE THROAT HOT LIQUID OTC
Generic Name and Formulations:
Acetaminophen 650mg, pheniramine maleate 20mg, phenylephrine HCl 10mg; pwd packets; apple cinnamon flavor; contains sodium 51mg, potassium 10mg per packet.
Novartis Consumer Health
Indications for THERAFLU FLU & SORE THROAT HOT LIQUID:
Minor aches and pains. Headache. Fever. Sneezing. Rhinorrhea. Nasal and sinus congestion. Itchy eyes, nose, throat. Sore throat.
Dissolve contents of 1 packet in 8oz of hot water; sip while hot. Consume entire drink within 10–15 minutes. Take every 4 hours; max 6 packets/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. Glaucoma. COPD. Asthma. GI or GU obstuction. Sodium-restricted diet. Discontinue if symptoms worsen or persist after 2–7 days. Pregnancy. Nursing mothers.
Analgesic + antihistamine + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers increase pressor effect of sympathomimetics. Antagonizes antihypertensives. Increased CNS effects with other CNS depressants.
Drowsiness, nervousness, dizziness, insomnia, anticholinergic effects, excitability in children; hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
- New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
- Peer-Led Education Helps Physicians Save Time With EHRs
- As Immigration Policies Tighten, Physician Shortage Concerns Grow